Jefferies’s $110 target on BBIO

BBIO Bridgebio Pharma Inc

$66.1 → $110 (+66%) by Oct 2027

Buy · reiterates · said Oct 5, 2026 · 12-month default horizon

Open: judged on the close on Oct 5, 2027

The article this target came from

Jefferies reiterates Buy on BridgeBio Pharma stock, $110 target

Investing.com · Oct 5, 2026

Jefferies reiterated a Buy rating on BridgeBio Pharma (NASDAQ:BBIO) with a price target of $110.00.

Jefferies’s track record → Bridgebio Pharma Inc →

A fact about what Jefferies published, as reported by Investing.com, not a recommendation from Dalsna Finance; Jefferies is not affiliated with this site.

Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.